Lascufloxacin

Lascufloxacin (trade name Lasvic) is an fluoroquinolone antibiotic drug for the treatment of bacterial infections. It has been approved since 2019 in Japan[1] to treat community-acquired pneumonia, otorhinolaryngological infections, and respiratory tract infections.[2]

Lascufloxacin
Clinical data
Trade namesLasvic
Other namesKRP-AM1977
Identifiers
  • 7-[(3S,4S)-3-[(Cyclopropylamino)methyl]-4-fluoropyrrolidin-1-yl]-6-fluoro-1-(2-fluoroethyl)-8-methoxy-4-oxoquinoline-3-carboxylic acid
CAS Number
PubChem CID
IUPHAR/BPS
ChemSpider
UNII
KEGG
Chemical and physical data
FormulaC21H24F3N3O4
Molar mass439.435 g·mol−1
3D model (JSmol)
  • COC1=C2C(=CC(=C1N3C[C@@H]([C@@H](C3)F)CNC4CC4)F)C(=O)C(=CN2CCF)C(=O)O

It has activity against various Gram-positive bacteria including Streptococcus pneumoniae[3] and Streptococcus anginosus.[4]

References
  1. "Kyorin Pharmaceutical Receives Marketing Approval for Oral Quinolone Antibacterial Agent Lasvic Tablets 75 mg" (PDF) (Press release). Kyorin Pharmaceutical Co. September 20, 2019. Retrieved July 3, 2021.
  2. "Lascufloxacin - Kyorin Pharmaceutical". Adis Insight. Retrieved July 3, 2021.
  3. Murata M, Kosai K, Yamauchi S, Sasaki D, Kaku N, Uno N, Morinaga Y, Hasegawa H, Miyazaki T, Izumikawa K, Mukae H, Yanagihara K (April 2018). "In Vitro Activity of Lascufloxacin against Streptococcus pneumoniae with Mutations in the Quinolone Resistance-Determining Regions". Antimicrob Agents Chemother. 62 (4). doi:10.1128/AAC.01971-17. PMC 5913943. PMID 29439959.
  4. Yamagishi Y, Matsukawa Y, Suematsu H, Mikamo H (December 2018). "In vitro activity of lascufloxacin, a novel fluoroquinolone antibacterial agent, against various clinical isolates of anaerobes and Streptococcus anginosus group". Anaerobe. 54: 61–64. doi:10.1016/j.anaerobe.2018.08.002. PMID 30114441. S2CID 52015090.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.